EMA Recommends Granting a Marketing Authorisation for Tarlatamab By Ogkologos - April 17, 2026 307 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the treatment of adult patients with extensive-stage SCLC Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR “If there is an under-representation of ethnic minority communities, there will... September 18, 2020 Patient Guide on Cancer Pain Management Now Available Also in French December 16, 2025 How to Get More Support From Your Oncology Pharmacist During Cancer February 24, 2021 Life-saving scheme to improve cancer screening among Muslim women July 20, 2023 Load more HOT NEWS Relugolix Approval Expected to Alter Treatment for Advanced Prostate Cancer NCI Initiative Aims to Boost CAR T-Cell Therapy Clinical Trials EMA Recommends Granting a Conditional Marketing Authorisation for Odronextamab FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory...
